RESCHEDULING OF 18FDG PET/CT PROCEDURES CAUSED BY HIGHER FASTING BLOOD SUGAR LEVEL: A CLINICAL AUDIT

Khalil Ahmed Khan, Gufran Khan, Sidra Khan, Nosheen Fatima, MASEEH UZ ZAMAN

Abstract


Abstract

Background: Fasting blood sugar (FBS) level is an important confounding factor having an impact on qualitative and quantitative aspects of 18-Flourodeoxy glucose Positron Emission Tomography and Computerized Tomography (18FDG PET/CT). FBS ≥200 mg% is an indication of rescheduling of procedure as recommended by various guidelines. Purpose of this clinical audit is to find out the frequency of rescheduling due to higher FBS and to explore the reason(s).

 

Material and Method: This audit was conducted at PET/CT services of Radiology Department Aga Khan University Hospital (AKUH) and consecutive 18FDG PET/CT data from 1.1.2017 till 30.06.2017 was collected. Cohort was segregated into those having FBS within and beyond institutional benchmark (FBS = <200 mg%). Root cause analyses (RCA) for rescheduled procedures caused by FBS beyond acceptable limits were made.

 

Results: During study period total 534 18FDG PET/CT procedures were performed (Mean age 52 ± 17 years with male to female ratio was 58:42%). Mean FBS was 109 ± 35 mg% with range of 52-285 mg%). FBS beyond benchmark was found in 12 (02%) patients who were rescheduled. RCA revealed inadequate understanding by patient / attendant and poor compliance to instructions briefed to them at time of appointment.

 

Conclusion: Frequency of rescheduling of 18FDG PET/CT procedures during audit period was significantly low. Focused counseling by receptionist and involving treating physician could further reduce the rescheduling incidence and avoid inconvenience to patient and financial loss caused by decay of available dose of 18FDG.

 

 

 

Background: Fasting blood sugar (FBS) level is an important confounding factor having an impact on qualitative and quantitative aspects of 18-Flourodeoxy glucose Positron Emission Tomography and Computerized Tomography (18FDG PET/CT). FBS ≥200 mg% is an indication of rescheduling of procedure as recommended by various guidelines. Purpose of this clinical audit is to find out the frequency of rescheduling due to higher FBS and to explore the reason(s).

 

Material and Method: This audit was conducted at PET/CT services of Radiology Department Aga Khan University Hospital (AKUH) and consecutive 18FDG PET/CT data from 1.1.2017 till 30.06.2017 was collected. Cohort was segregated into those having FBS within and beyond institutional benchmark (FBS = <200 mg%). Root cause analyses (RCA) for rescheduled procedures caused by FBS beyond acceptable limits were made.

 

Results: During study period total 534 18FDG PET/CT procedures were performed (Mean age 52 ± 17 years with male to female ratio was 58:42%). Mean FBS was 109 ± 35 mg% with range of 52-285 mg%). FBS beyond benchmark was found in 12 (02%) patients who were rescheduled. RCA revealed inadequate understanding by patient / attendant and poor compliance to instructions briefed to them at time of appointment.

 

Conclusion: Frequency of rescheduling of 18FDG PET/CT procedures during audit period was significantly low. Focused counseling by receptionist and involving treating physician could further reduce the rescheduling incidence and avoid inconvenience to patient and financial loss caused by decay of available dose of 18FDG.

 

 

 

 

 

 


Full Text:

PDF

References


. Hahn T, Hofmann W, Reich O, Lang I, Desoye G. Hyperglycaemia regulates the glucose-transport system of clonal choriocarcinoma cells in vitro. A potential molecular mechanism contributing to the adjunct of glucose in tumour therapy. Int J Cancer 1998; 78: 353–360.

. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG-PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998; 39: 1030–1033.

. Sprinz C, Zanon M, Altmayer S, Klaus G, Marchiori E, Hochhegger B. Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysis on 5623 patients. Sci Rep. 2018; 8: 2126.

. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42(2):328-54.

. White MK, McCubrey JA. Changes in glucose transport associated with malignant transformation. Int J Oncol 1995; 7: 701–712.

. Zhuang HM, Cortes-Blanco A, Pourdehnad M. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun. 2001;22:1123–1128.

. Artor A, Iuele F, Merenda N, Pisani AR, Notaristefano A, Giuseppe R. 18F-FDGPET/CT: diabetes and hyperglycaemia. Nuclear Medicine Review 2013, 16, 2: 57–61


Refbacks

  • There are currently no refbacks.


© Copyright PJR 2008-